Early observations and pilot data that first suggested a new direction
In 2002, Alain Cribier performed the first-in-human transcatheter aortic valve implantation in a 57-year-old patient with inoperable calcific aortic stenosis and cardiogenic shock. This proof-of-concept demonstration opened an entirely new frontier in structural heart intervention. The PARTNER 1B trial then tested TAVR against standard medical therapy in patients deemed inoperable, enrolling 358 patients and demonstrating a dramatic 20% absolute reduction in 1-year all-cause mortality with TAVR (30.7% vs 50.7%). At 5 years, mortality remained significantly lower with TAVR (71.8% vs 93.6%; HR 0.50). These early data established TAVR as a life-saving intervention for patients with no surgical option.
Landmark RCTs and pivotal trials that established the evidence base
The PARTNER 1A trial established noninferiority of TAVR to surgical aortic valve replacement in high-risk patients. Among 699 randomized patients (mean STS score 11.7%), TAVR demonstrated comparable 1-year mortality to SAVR, though with higher rates of vascular complications and paravalvular regurgitation. At 5 years, outcomes remained equivalent. The PARTNER 2A trial extended these findings to intermediate-risk patients, randomizing 2,032 patients and finding that TAVR with the SAPIEN XT valve was noninferior to surgery for the composite of death or disabling stroke at 2 years (19.3% vs 21.1%). In the transfemoral-access cohort, a trend favoring TAVR emerged.
Follow-up studies, subgroup analyses, and real-world validation
Two landmark trials in 2019 extended TAVR to low-surgical-risk patients. PARTNER 3 randomized 1,000 patients (mean STS 1.9%) to TAVR with the SAPIEN 3 valve vs SAVR and demonstrated superiority of TAVR for the composite of death, stroke, or rehospitalization at 1 year (8.5% vs 15.1%; HR 0.54, p=0.001). The Evolut Low Risk trial randomized 1,468 patients to self-expanding TAVR vs SAVR and confirmed noninferiority, with the composite of death or disabling stroke at 24 months occurring in 5.3% vs 6.7%. However, 7-year PARTNER 3 data showed convergence of outcomes, raising questions about long-term valve durability.
Integration into clinical practice guidelines and recommendations
The 2020 ACC/AHA Valvular Heart Disease guidelines incorporated TAVR as a Class I recommendation for patients with severe symptomatic aortic stenosis at high or prohibitive surgical risk, and as a reasonable alternative (Class IIa) for patients at intermediate risk. Following the low-risk trials, TAVR gained acceptance across the full risk spectrum, with shared decision-making emphasized for younger patients where long-term durability data remain limited.
ACC/AHA
TAVR recommended for severe AS at high/prohibitive risk (Class I); reasonable alternative at intermediate risk (Class IIa); option for low-risk patients with appropriate anatomy
ESC/EACTS
TAVR recommended for patients ≥75 years or at high surgical risk; Heart Team decision for those 65-75 based on individual factors
Now
Current standard of care and ongoing research directions
TAVR has become the dominant modality for aortic stenosis treatment globally, with over 200,000 procedures performed annually. The critical frontier is long-term valve durability, particularly in younger low-risk patients who may outlive their bioprosthetic valves. Seven-year PARTNER 3 data showed convergence of outcomes between TAVR and SAVR, underscoring the need for longer follow-up. Valve-in-valve TAVR offers a potential solution for structural valve deterioration. Active investigation continues into TAVR for bicuspid valve disease, pure aortic regurgitation, and asymptomatic severe AS.
How does TAVR compare to surgical valve replacement in low-risk patients?+
The PARTNER 3 and Evolut Low Risk trials demonstrated that TAVR was noninferior (and in the case of PARTNER 3, superior at 1 year) to SAVR in low-risk patients. However, 7-year data from PARTNER 3 showed convergence of outcomes, suggesting early advantages may not persist long-term.
What is the main concern about using TAVR in younger patients?+
The primary concern is valve durability. Current transcatheter valves have robust data out to 5-7 years, but long-term structural valve deterioration rates beyond 10-15 years are unknown. Younger patients may require reintervention, and while valve-in-valve TAVR is feasible, its long-term effectiveness is still under investigation.
What was the historical progression of TAVR indication expansion?+
TAVR expanded progressively from inoperable patients (PARTNER 1B, 2010) to high-risk (PARTNER 1A, 2011), intermediate-risk (PARTNER 2, 2016), and finally low-risk patients (PARTNER 3 and Evolut Low Risk, 2019). Each expansion was supported by randomized controlled trial evidence demonstrating at least noninferiority to surgery.
